- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Gilead CEO Dan O'Day nets $28.4M pay package as security and travel costs top $2M | ||
| Mo | Insmed sets up Arikayce for a significant label expansion on new ph. 3 data | ||
| Mo | EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race | ||
| Mo | FDA mandates label updates to common Parkinson's meds based on seizure risk finding | ||
| Mo | Novartis joins Lilly, AstraZeneca in China expansion with $480M commitment to boost manufacturing, R&D | ||
| Mo | Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's Rybrevant | ||
| Mo | FDA solicits feedback on controversial national priority voucher review pathway | ||
| 20.03. | Sanofi backs 2 more documentary films about rare blood disorders | ||
| 20.03. | With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper generics | ||
| 20.03. | ACIP member's miscommunication on vaccine panel's future adds to confusion after court ruling | ||
| 20.03. | Rhythm's Imcivree scores 'transformative' FDA approval in brain-damage related obesity | ||
| 19.03. | CSL warns of supply shortfall, treatment delays for hemophilia gene therapy Hemgenix | ||
| 19.03. | Novo's Wegovy HD passes muster under FDA national priority voucher program | ||
| 19.03. | Maryland bill calls for more transparency in pharma's disease awareness campaigns | ||
| 19.03. | Collegium ponies up $650M to gain ADHD drug Azstarys from Corium | ||
| 19.03. | After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease | ||
| 19.03. | AstraZeneca to build cell therapy manufacturing hub, R&D center in Shanghai | ||
| 19.03. | CDMO Axplora to pump $60M into Italian complex API plant | ||
| 18.03. | With downgrade, HSBC casts doubt about Lilly's 'stairway to heaven' trajectory | ||
| 18.03. | TrumpRx's 'world's lowest' drug price claims fall short in global comparison: NYT | ||
| 18.03. | J&J, Protagonist's 'game-changer' once-daily psoriasis pill Icotyde nabs FDA approval | ||
| 18.03. | BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists | ||
| 18.03. | Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio | ||
| 18.03. | Gates-backed TerraPower Isotopes blueprints $450M plant to supply next wave of radiopharmaceuticals | ||
| 17.03. | GSK's management of Flovent allowed it to 'game the system': Hassan |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.